Contract drug manufacturer Patheon has named former chief executive of Biogen Idec to be the company’s new CEO.
James Mullen’s appointment to lead Patheon (TSX:PTI), based in North Carolina’s Research Triangle Park, is effective immediately. He replaces former Patheon CEO Wesley Wheeler, who resigned in December. In the announcement of Wheeler’s departure, Patheon’s Chairman of the Board Ramsey Frank said that the board decided a new CEO was needed to move the company forward.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Mullen is no stranger to North Carolina as Weston, Massachusetts-based Biogen Idec (NASDAQ:BIIB) employs about 800 at an R&D and manufacturing facility in RTP. Mullen was Biogen Idec’s CEO for 10 years. Prior to the merger of Biogen and Idec Pharmaceuticals, Mullen was CEO and president of Biogen. His career in the pharmaceutical industry spans 30 years. He retired from Biogen Idec last June.
Patheon makes marketed drugs for pharmaceutical companies. The company also makes drugs for companies testing drugs in clinical trials. The company relocated its headquarters to RTP from Toronto in 2008, though the company still maintains significant manufacturing operations in Canada.
